Related Experiment Video

Updated: May 11, 2026

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

MicroRNAs as potential therapeutic targets in kidney disease

Ivan G Gomez1, Monica Grafals, Didier Portilla

  • 1Division of Nephrology, Seattle, WA, USA. igomez@uw.edu

Journal of the Formosan Medical Association = Taiwan Yi Zhi
|May 11, 2013
PubMed

Insights

Fibrosis is a key feature of chronic kidney disease (CKD). Targeting dysregulated microRNAs offers a promising new therapeutic strategy to treat kidney damage and slow CKD progression.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Biomedical Research

Background:

  • Fibrosis is a major characteristic of chronic kidney disease (CKD), affecting kidney structure and function.
  • Current treatments for CKD progression primarily involve angiotensin receptor blockers, highlighting a need for novel therapeutic approaches.
  • Dysregulation of microRNAs has been observed in both human and animal models of CKD.

Purpose of the Study:

  • To review the evidence supporting microRNAs as therapeutic targets for CKD.
  • To explore the potential of blocking dysregulated microRNAs to treat kidney fibrosis and CKD progression.

Main Methods:

  • Literature review of studies investigating microRNA dysregulation in CKD.
  • Analysis of research on the role of specific microRNAs in kidney fibrosis.
  • Evaluation of preclinical data on microRNA-targeted therapies for kidney disease.

Main Results:

  • Multiple microRNAs are confirmed to be dysregulated in various models of CKD.
  • Evidence suggests that modulating these microRNAs can impact fibrotic pathways in the kidney.
  • Preclinical studies indicate the potential efficacy of microRNA-based interventions.

Conclusions:

  • Dysregulated microRNAs represent a significant therapeutic target for managing CKD.
  • Blocking the activity of specific microRNAs may offer a novel strategy to combat kidney fibrosis.
  • Further research into microRNA therapeutics could lead to new treatments for chronic kidney disease.

More Related Videos

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues12:21

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues

Published on: November 30, 2013

A Quantitative Detection Method for MicroRNAs in the Kidney of an Ischemic Kidney Injury Mouse Model07:01

A Quantitative Detection Method for MicroRNAs in the Kidney of an Ischemic Kidney Injury Mouse Model

Published on: September 11, 2020

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Nephrons01:10

Nephrons

The kidneys are intricate organs with millions of working units known as nephrons. Each nephron features two major structures: the renal corpuscle, which facilitates blood plasma filtration, and the renal tubule, which handles the glomerular filtrate. Blood supply is directly linked to the nephrons. The renal corpuscle consists of the glomerulus, a capillary network, and the Bowman's capsule, a double-walled epithelial structure that encases the glomerulus. The filtering of blood plasma happens...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...